SSG
ALXN

Summit Securities Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Summit Securities Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,800
Closed -$539K – 531
2020
Q2 		$539K Buy
+4,800
New +$510K 0.07% 226
2013
Q4 		– Sell
-300
Closed -$35K – 616
2013
Q3 		$35K Buy
+300
New +$32.9K 0.01% 199

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Summit Securities Group's ALXN Position: Q3 2020 in Review

Summit Securities Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 4,800 shares — an estimated $539K sold.

Summit Securities Group first reported a position in ALXN in Q3 2013 and held it in 2 quarters. The position peaked at $539K in Q2 2020. 707 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

  • Summit Securities Group reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Summit Securities Group sold 4,800 Alexion Pharmaceuticals shares in Q3 2020, an estimated $539K.
  • Summit Securities Group first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 2 quarters.
  • Summit Securities Group's Alexion Pharmaceuticals position peaked at $539K in Q2 2020.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Summit Securities Group's 13F filing for Q3 2020, filed 19 Oct 2020.